In patients with Huntington disease, vesicular monoamine transporter 2 inhibitors (VMAT2is) treatment improved chorea without significant changes in adverse effects or depressive symptoms.

This website uses a security service to protect against malicious bots. This page is displayed while the website verifies you are not a bot.